Conversion to Disposable Cystoscopes Decreased Post-procedure Encounters and Infections Compared to Reusable Cystoscopes.


Journal

Urology practice
ISSN: 2352-0787
Titre abrégé: Urol Pract
Pays: United States
ID NLM: 101635343

Informations de publication

Date de publication:
07 2023
Historique:
medline: 22 6 2023
pubmed: 25 5 2023
entrez: 25 5 2023
Statut: ppublish

Résumé

We evaluated for differences in post-procedure 30-day encounters or infections following office cystoscopy using disposable vs reusable cystoscopes. Cystoscopies performed from June to September 2020 and from February to May 2021 in our outpatient practice were retrospectively reviewed. The 2020 cystoscopies were performed with reusable cystoscopes, and the 2021 cystoscopies were performed with disposable cystoscopes. The primary outcome was the number of post-procedural 30-day encounters defined as phone calls, patient portal messages, emergency department visits, hospitalizations, or clinic appointments related to post-procedural complications such as dysuria, hematuria, or fever. Culture-proven urinary tract infection within 30 days of cystoscopy was evaluated as a secondary outcome. We identified 1,000 cystoscopies, including 494 with disposable cystoscopes and 506 with reusable cystoscopes. Demographics were similar between groups. The most common indication for cystoscopy in both groups was suspicion of bladder cancer (disposable: 153 [30.2%] and reusable: 143 [28.9%]). Reusable cystoscopes were associated with a higher number of 30-day encounters (35 [7.1%] vs 11 [2.2%], Disposable cystoscopes were associated with a lower number of post-procedure encounters and positive urine cultures compared to reusable cystoscopes.

Identifiants

pubmed: 37228224
doi: 10.1097/UPJ.0000000000000410
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

312-317

Auteurs

Laura E Geldmaker (LE)

Department of Urology, Mayo Clinic, Jacksonville, Florida.

Bryce A Baird (BA)

Department of Urology, Mayo Clinic, Jacksonville, Florida.

Timothy D Lyon (TD)

Department of Urology, Mayo Clinic, Jacksonville, Florida.

Eric J Regele (EJ)

Department of Urology, Mayo Clinic, Jacksonville, Florida.

Ethan J Wajswol (EJ)

Department of Urology, Mayo Clinic, Jacksonville, Florida.

Ram A Pathak (RA)

Department of Urology, Mayo Clinic, Jacksonville, Florida.

Steven P Petrou (SP)

Department of Urology, Mayo Clinic, Jacksonville, Florida.

Daniela A Haehn (DA)

Department of Urology, Mayo Clinic, Jacksonville, Florida.

Nikunj M Gajarawala (NM)

Department of Urology, Mayo Clinic, Jacksonville, Florida.

Colleen T Ball (CT)

Division of Clinical Trials and Biostatistics, Mayo Clinic, Jacksonville, Florida.

Gregory A Broderick (GA)

Department of Urology, Mayo Clinic, Jacksonville, Florida.

David D Thiel (DD)

Department of Urology, Mayo Clinic, Jacksonville, Florida.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH